These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 20544639)
41. Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly. Park SH; Ku CR; Moon JH; Kim EH; Kim SH; Lee EJ J Clin Endocrinol Metab; 2018 Mar; 103(3):909-916. PubMed ID: 29272449 [TBL] [Abstract][Full Text] [Related]
42. A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both? Schwarz ER; Jammula P; Gupta R; Rosanio S J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):232-44. PubMed ID: 17220469 [TBL] [Abstract][Full Text] [Related]
43. Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Wang YY; Higham C; Kearney T; Davis JR; Trainer P; Gnanalingham KK Clin Endocrinol (Oxf); 2012 Mar; 76(3):399-406. PubMed ID: 21824170 [TBL] [Abstract][Full Text] [Related]
44. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR. Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028 [TBL] [Abstract][Full Text] [Related]
46. Recent results of secondary transnasal surgery for residual or recurring acromegaly. Abe T; Lüdecke DK Neurosurgery; 1998 May; 42(5):1013-21; discussion 1021-2. PubMed ID: 9588545 [TBL] [Abstract][Full Text] [Related]
47. A case of acromegaly in pregnancy: concomitant transsphenoidal adenomectomy and cesarean section. Guven S; Durukan T; Berker M; Basaran A; Saygan-Karamursel B; Palaoglu S J Matern Fetal Neonatal Med; 2006 Jan; 19(1):69-71. PubMed ID: 16492596 [TBL] [Abstract][Full Text] [Related]
48. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132 [TBL] [Abstract][Full Text] [Related]
49. Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. Zirkzee EJ; Corssmit EP; Biermasz NR; Brouwer PA; Wiggers-De Bruine FT; Kroft LJ; Van Buchem MA; Roelfsema F; Pereira AM; Smit JW; Romijn JA J Clin Endocrinol Metab; 2004 Sep; 89(9):4320-4. PubMed ID: 15356027 [TBL] [Abstract][Full Text] [Related]
50. Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly. Kim JH; Hur KY; Lee JH; Lee JH; Se YB; Kim HI; Lee SH; Nam DH; Kim SY; Kim KW; Kong DS; Kim YH World Neurosurg; 2017 Aug; 104():272-278. PubMed ID: 28465267 [TBL] [Abstract][Full Text] [Related]
52. Proton stereotactic radiosurgery in management of persistent acromegaly. Petit JH; Biller BM; Coen JJ; Swearingen B; Ancukiewicz M; Bussiere M; Chapman P; Klibanski A; Loeffler JS Endocr Pract; 2007; 13(7):726-34. PubMed ID: 18194929 [TBL] [Abstract][Full Text] [Related]
53. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693 [TBL] [Abstract][Full Text] [Related]
54. [Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR]. Correa LL; Taboada GF; Van Haute FR; Casini AF; Balarini GA; Vieira Neto L; Machado Ede O; Fontes R; Andrade CC; Schrank Y; Gadelha MR Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):55-64. PubMed ID: 18345397 [TBL] [Abstract][Full Text] [Related]
55. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL Pituitary; 2007; 10(3):233-6. PubMed ID: 17541750 [TBL] [Abstract][Full Text] [Related]
57. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control. Tirosh A; Papadakis GZ; Chittiboina P; Lyssikatos C; Belyavskaya E; Keil M; Lodish MB; Stratakis CA Horm Metab Res; 2017 Jun; 49(6):440-445. PubMed ID: 28472827 [TBL] [Abstract][Full Text] [Related]
58. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332 [TBL] [Abstract][Full Text] [Related]
59. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Frohman LA; Bonert V Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717 [TBL] [Abstract][Full Text] [Related]
60. Octreotide LAR for the treatment of acromegaly. Vallette S; Serri O Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]